Key Upcoming Milestones
Regulatory Submissions: Following the positive bioequivalence study results, LTR Pharma is expected to submit regulatory applications to the Therapeutic Goods Administration (TGA) in Australia and the U.S. Food and Drug Administration (FDA) within the next 6 to 12 months.These submissions are crucial steps toward commercialization.ltrpharma.com
Market Launch: If regulatory approvals are obtained, the commercial launch of SPONTAN® could occur in late 2025 or early 2026, potentially leading to increased revenue and investor interest.
Financial Reports: LTR Pharma's upcoming financial reports, including the annual report expected around August 29, 2025, will provide insights into the company's financial health and progress.
nothing to see here till then
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.015(5.36%) |
Mkt cap ! $33.02M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 31.0¢ | 28.5¢ | $112.8K | 382.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 19244 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 64264 | 2 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| LTP (ASX) Chart |